Sources say Baxter's near an agreement with EU regulators in $4B Gambro merger

July 11, 2013 by Sony Salzman

Anonymous sources say that Baxter is nearing an agreement with European Commission anti-trust regulators over the $4 billion acquisition of Swedish dialysis giant Gambro AB.

Baxter proposes fixes to EU’s antitrust concerns

Healthcare giant Baxter (NYSE:BAX) may be on the verge of closing its $4 billion buyout of Swedish dialysis devices maker Gambro AB after offering to divest some of its assets in order to appease European regulators, according to anonymous sources cited by Reuters.

"People familiar with the matter" told the news wire that negotiations with EU regulators are moving forward and that Baxter offered to sell off its global continuous renal replacement therapy business in order to stem anti-trust concerns.

Sign up to get our free newsletters delivered right to your inbox.

A Baxter representative contacted by declined to comment on the rumors, saying that the device maker plans to release the details of the high-stakes merger during its 3rd quarter. The merger would make Baxter the 2nd-biggest player in the dialysis market, according to Reuters.

European Commission anti-trust regulators later this month will make an official announcement on the negotiations surrounding the pending merger. The agency delayed its decision deadline last week in order to extend negotiations.